Observational studyEuropean heart journal. Quality of care & clinical outcomes2026
A nationwide study of the economic burden of obstructive hypertrophic cardiomyopathy in France.
Observational study in European heart journal. Quality of care & clinical outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical characteristics, treatment patterns, and costs among hospitalised patients with cardiomyopathy: a multicentre retrospective tertiary-hospital study across China.The Lancet regional health. Western Pacific · 2026Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
aimThis study describes economic burden of obstructive hypertrophic cardiomyopathy (HCM) in France, with consideration of disease severity as measured by New York Heart Association (NYHA) class. METHODS AND
resultsThis observational, retrospective study used data from the French National Health Data System. Adults (≥18) with at least one disease related hospitalization during 2012-18 were included. Patients with <1-year follow-up or phenocopy disorders were excluded. Patients were stratified by disease severity class based on disease specific treatments and symptoms. Healthcare resources use, and costs were estimated per patient-year (PY). Annual cost before and after septal reduction therapies (SRT) was estimated. Overall, 6823 patients were identified (baseline NYHA class I-IV: 4%, 32%, 60%, and 4%, respectively). Mean (standard deviation) follow-up was 4.4 (2.5) years, comprising 30 228 PYs. Total burden was €388 million (€12 824 per PY), and higher NYHA class was associated with higher cost per patient year: €8881 and €22 818 for classes I and IV, respectively. Hospitalizations accounted for most costs (54%); 71% were cardiovascular-related hospitalizations, 46% disease-related. Mean cost per PY was lower 1 year before vs. after SRT, including the intervention (€13 726 vs. €18 565). Mean sick-leave-related costs per PY were €310, €673, €757, and €774 for classes I-IV, respectively.
conclusionObstructive HCM has a high economic burden driven by cardiovascular hospitalizations. Higher disease severity yielded higher costs associated with medical care and sick leave than lower classes. Results support need for new therapies to improve both symptoms and disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.